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Randolph J. Noelle highlighted by a reduction of organized granuloma for-
mation, that increased appearance of poorly differenti-Department of Microbiology
ated macrophages together with reduced ulceration andDartmouth Medical School
necrosis. As found in the study cited above, no grossLebanon, New Hampshire 03756
changes in T or B cell populations could account for
At the onset, it appeared that immunology had finally the altered susceptibility to infection by the parasite.
identified a molecule with a singular function in the regu- Reduced IgG and IgE antibody titers to parasite antigens
lation of humoral immunity. Early studies in mice and also were noted in the CD40L2/2 mice. Assessment of
mutations in humans (hyper immunoglobulin M syn- T cell function in the CD40L2/2 mice revealed a lowered
drome; HIM) all pointed an accusatory finger at the li- T cell proliferative response to parasite antigens and a
gand for CD40 (gp39; CD40L) as the cardinal element virtual absence of IFNg and lymphotoxin±tumor necrosis
in the initiation of humoral immune responses to thymus- factor production. This was similar to the defect in in-
dependent (TD) antigens (reviewed by Durie et al., flammatory cytokines observed in CD40L2/2 mice in-
1994b). However, just as interleukin-2 (IL-2) and IL-4 fected with L. major. Interestingly, attempts to protect
have lost their identity as unique T cell and B cell growth mice from infection with vaccination to L. amazonensis
proved futile in the CD40L2/2 mice, yet effective in wild-factors, respectively, so CD40L is losing its identity as
type mice. Central to the diminished resistance to L.an effector molecule that is exclusively involved in the
amazonensis in the CD40L2/2 is a reduced capacity ofregulation of humoral immunity. A recent flurry of manu-
macrophages to exert antiparasitic responses such asscripts underscore the importance of this ligand±
nitric oxide (NO) production. However, unlike thestudiesreceptor pair in host defense outside of its central func-
cited above, studies with L. amazonensis showed thattion in the regulation of humoral immunity.
the production of IL-12 was comparable to wild-type
mice. This lead the authors to conclude that the major
Cell-Mediated Immunity contributing defect to increased susceptibility to L. ama-
CD40 and Immunity to Microbes zonensis infection was diminished macrophage activa-
Using mice whose CD40L or CD40 gene was disrupted tion and NO production.
by homologous recombination, three reports have re- Early studies describing the defects in CD40L2/2 and
cently established that CD40L is required for protective CD402/2 mice revealed that disruption of either the re-
cell-mediated immunity to Leishmania major and to ceptor or the ligand or, in fact, treatment of mice with
Leishmania amazonensis (Campbell et al., 1996; Kama- a neutralizing anti-CD40L antibody, resulted in identical
naka et al., 1996; Soong et al., 1996). In the CD40L- phenotypic changes in the humoral immune response.
defective mice backbred onto a genetic background Similarly, it has been reported (Kamanaka et al., 1996)
normally resistant to progressive infection with L. major, that CD40-deficient mice, like the CD40L-deficient mice,
the acquisition of a susceptible phenotype was ob- have an increased susceptibility to L. major, and cannot
served (Campbell et al., 1996). The evaluation of the T resolve the infection. As observed in the CD40L2/2 mice
cell priming in these mice showed that the T cells from infected with L. major, the CD402/2 mice produced low-
the wild-type infected mice produced 100- to 150-fold ered amounts of IFNg and IL-12. In the CD402/2 mice,
more interferon g (IFNg) then T cells from CD40L2/2 mice. higher levels of IL-4 were observed. All three studies
Furthermore, splenocytes from CD40L2/2 mice pro- strongly suggest that in the absence of CD40 signaling,
duced far lower levels of IL-12 upon antigen stimulation T cell responses are polarized towards a T helper (Th)2-
when compared with splenocytes from wild-type mice. type response.
The inability of CD40L2/2 splenocytes to produce IL-12 CD40 and Macrophage Function
resulted from the inability of CD40L2/2 T cells to induce The studies cited above underscore the important role
IL-12 and was not due to an intrinsic defect in the macro- that CD40 and its ligand play in host defense, over and
phage compartment. Finally, a causative relationship above the role that this ligand±receptor pair play in hu-
between CD40L-induced IL-12 production and disease moral immunity. Along with the increased susceptibil-
progression was shown by the observation that IL-12 ity to Leishmania, there is also an increased susceptibil-
administration ªcuredº CD40L2/2 mice of L. major in- ity to Pneumocystis carrini. This increased susceptibility
fection. has been observed in three contexts. First, treatment of
Unlike L. major, where selected strains of mice are mice with anti-CD40L diminished their ability to clear
resistant to infection, most inbred strains of mice are Pneumocystis (Wiley and Harmsen, 1995). Second, HIM
susceptible to L. amazonensis infection. When the patients have a exceedingly high incidence of infection
CD40L gene was disrupted, the susceptibility of mice with this pathogen (Notarangelo et al., 1992). Finally, my
to L. amazonensis was greatly increased (Soong et al., colleagues and I have observed increased susceptibility
1996). When the tissue parasite burden in wild-type and when our entire colony of CD40L2/2 mice succumbed
CD40L2/2 mice was compared, the CD40L2/2 mouse bur- to Pneumocystis infection.
den was 50- to 60-fold higher and this difference in- The diminished function of macrophages in the ab-
creasedat later times during the infection. Immunohisto- sence of CD40 signaling may result due to a reduced
chemical analysis of infected areas illustrated that in the inflammatory response from T cells. It is now recognized
that CD40L induces polarity in the T cell compartmentCD40L2/2 there was a reduced inflammatory response,
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through its ability to trigger macrophages or dendritic B cells and anti-CD40L was used to induce transplant
tolerance. Pretreatment of mice in this way renderedcells (DCs) to produce IL-12 in the presence of IFNg
(Shu et al., 1995). That is, when CD40L is adequately mice allotolerant and allowed the long-term engraftment
of allogeneic pancreatic islet cells (Parker et al., 1995).expressed, an effective loop for the induction of potent
Th1-type inflammatory responses will be evoked. Fur- The question emerges as to whether a CD40 signal is
critical for other APCs, i.e., DCs, to provide adequatether evidence in support of this scenario is provided by
the results of anti-CD40L administration in a model of costimulatory activity. Certainly, evidence does exist
that at least some DCs express abundant levels ofinflammatory bowel disease (IBD) (Stuber et al., 1996).
Rectal instillation of an inflammatory hapten incites IBD, B7-2 in vivo and that B7-2 is the primary ligand in DC-
induced T cell costimulation (Inaba et al., 1994; Larsenwhose hallmarks are elevated Th1 cytokines, IL-12
production, and inflammatory pathology. Treatment et al., 1994). Nonetheless, numerous DC populations,
like the Langerhan cells of the skin, have low levels ofwith anti-CD40L antibody prevents the inflammatory
response and encourages the priming of Th2-type B7-2 until up-regulated expression is driven by cyto-
kines or CD40 triggering (Peguet et al., 1995). Functionalcells. Consistent with an anti-inflammatory role for anti-
CD40L, anti-CD40L prevents and appears to arrest the studies strongly implicate CD40 as an important media-
tor of APC function. First, in studies of graft-versus-hostdevelopment and progression of experimental allergic
encephalomyelitis (EAE), a T cell±mediated inflamma- disease (GVHD), it has been shown that brief treatment
with anti-CD40L prevents the generation of anti-hosttory response in the central nervous system (CNS) (Ger-
ritse et al., 1996). In this context, histological evidence cytotoxic T cells and prevents the onset of disease (Du-
rie et al., 1994a). All of the evidence to date in the GVHDsuggested that macrophages or microglia were the
prominent CD40-bearing cells in the CNS of EAE mice system suggests that the alloreactive T cells are being
rendered tolerant in the absence of CD40 signaling. Inor multiple sclerosis patients.
As stated above, the influence of CD40L on macro- addition to this study, other studies have shown that
CD40L2/2 mice are defective in T cell priming to proteinphage activities is likely broad. In addition to its apparent
positive impact on the production of inflammatory cyto- antigens in complete Freund's adjuvant. This study di-
rectly illustrated that the in vivo expansion of antigen-kines, CD40 also plays a direct role in microbicidal activ-
ity of macrophages. In one study cited above (Soong et specific T cells was impaired in the absence of ligand
(Grewal et al., 1995). Taken together, these data stronglyal., 1996), it was concluded that the lack of inducible
NO activitywas the leading cause of increased suscepti- suggest that CD40L may play an indirect role in T cell
priming, via the induction of costimulatory activity. Inbility to infection. Supportive evidence for an important
role of CD40 in the regulation of NO comes from studies our own experience, however, this appears not to be a
hard and fast rule, since we have shown that one canthat directly implicate CD40L in triggering NO in macro-
phages in vitro (Tian et al., 1995; Stout et al., 1996). prime helper T cells to sheep red blood cells in the
absence of CD40L (Foy et al., 1993). Therefore, unlikeCD40L regulation of inducible NO production has also
been observed in the context of allogeneic organ trans- the essential function of CD40L in TD humoral immunity,
the capacity of CD40L in the regulation of APC functionplant, whereby anti-CD40L allowed the long-term sur-
vival of cardiac transplants and this long-term survival may be supplanted by other immune activities. For ex-
ample, GM-CSF and IL-4 are potent inducers of B7-2was correlated with the block by anti-CD40L of inducible
NO synthase (Larsen et al., 1996). Beyond its influence on dendritic cells and B cells, respectively (Hathcock
et al., 1994), and may circumvent the need for CD40on microbicidal activity, CD40L also induces macro-
phages to produce many key proinflammatory cytokines triggering. This may be the reason why no apparent
defects indelayed-type hypersensitivityhave been com-like tumor necrosis factor a, IL-1b, IL-6, and IL-8 (Kiener
et al., 1995). Therefore, CD40L appears to be a multipur- monly observed in HIM patients.
CD40 and the Regulation of Adhesionpose macrophage activator involved in the up-regula-
tion of microbicidal activity, antigen presentation, and Anti-CD40L has been shown to block the development
of a number of T cell±mediated autoimmune diseases,costimulation, as well as the induction of proinflamma-
tory and inflammatory cytokines. including collagen-induced arthritis (Durie et al., 1993),
autoimmune oophoritis (Griggs et al., 1996), and EAECD40 and APC Function
The role that CD40 plays in the regulation of antigen- (Gerritse et al., 1996). In each of these examples, a re-
duction in T cell infiltration into the target organ/tissuepresenting cell (APC) activity isbest exemplified by stud-
ies using B cells as APCs. Resting B cells express mea- was noted. In at least some of these examples, the lack
of infiltration can not be explained by a lack in T cellger APC activity. A number of studies have shown that
triggering via CD40 is an effective means of increasing priming (Griggs et al., 1996). For example, it has been
shown that in the presence of anti-CD40L, T cell primingthe APC activity of B cells, most likely through the up-
regulation of B7-1 and B7-2 (Roy et al., 1994; Ranheim to a autoantigenic peptide induces increases in T cell
precursor frequency similar to that observed in its ab-and Kipps, 1995). The role of CD40±CD40L in regulating
the APC capacity of B cells has recently been docu- sence; yet no T cell infiltration into the target organ was
observed (Griggs et al., 1996). Therefore, how may anti-mented by showing that the combined administration
of anti-CD40L and allogeneic B cells can diminish allo- CD40L interfere with the trafficking of primed T cells
into target organs? Three papers have shown that CD40specific cytotoxic T lymphocyte and mixed lymphocyte
responses (Buhlmann et al., 1995). This observation was can regulate the expression of adhesion molecules on
endothelial cells (Hollenbaugh et al., 1995; Karmann etapplied to a system of ªdonor-specific transfusionº tol-
erance, whereby pretreatment of mice with allogeneic al.,1995; Yellin etal., 1995). Endothelial cells wereshown
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to express heightened levels of CD40 in inflammatory multimeric receptor, can transduce a costimulatory sig-
nal to the T cell (Cayabyab et al., 1994). We have shownskin disease; it also was shown that triggering of CD40
induced increased leukocyte adhesion as well as the up- that one can effectively in vivo prime CD402/2 T cells
with allogeneic B cells to levels observed with wild-typeregulation of VCAM, ICAM, and E-selectin. Therefore,
CD40L±CD40 interactions may play an important role in T cells, if the allogeneic B cells are first activated with
CD40L in vitro. This argues against a mandatory role forthe extravasation of activated T cells into the target
organ and their accumulation, as well. CD40L engagement in the process of T cell priming, and
supports the hypothesis that the function of CD40L inCD40L and Its Impact on Inflammation
How can blockade of a single effector molecule exert T cell priming is in the activation of the APC. The issue
of whether the engagement of CD40L by its receptorsuch profound effects on cell-mediated immunity? It is
clear that the lack of CD40L (or the administration of directly costimulates T cell activation demands further
study before there is a decisive answer.anti-CD40L) blocks multiple immune mechanisms that
are responsible for the development of inflammation. CD40L and Its Role in GC Maintenance
A most intriguing finding concerning the role of CD40L isFirst, lack of CD40L function either alters or diminishes
the priming and expansion of T cells in response to that the administration of anti-CD40L causes the abrupt
disappearance of preeÈ xisting GCs (Han et al., 1995).antigen, and polarizes the course of T cell differentiation
toward a Th2 response. This effect is due to the role of It has been well established that GC B cells acutely
apoptose upon isolation and that CD40 ligation can ªres-CD40L in the regulation of costimulatory molecules on
APC, or in the regulation of IL-12 production, or both. cueº them from death (Liu et al., 1992). Therefore, the
obvious reason why anti-CD40L treatment causes theSecond, even though some effector T cells may be gen-
erated in the absence of CD40L, their ability to traffic loss of GCs is due to increased apoptosis. However,
reported findings suggest that apoptosis is not theto the appropriate target organ may be diminished. One
would anticipate that the lack of CD40L will interfere cause for the rapid disappearance of GCs. This leaves
at least two possibilities. First, that anti-CD40L shutswith the localization of the effector cells in the target
organ by prohibiting the up-regulation of adhesion mole- off the influx of B cells into GCs; however, influx into
the GC appears to end long before the onset of anti-cules required for effector T cell diapedesis and accu-
mulation. Third, even though some effector T cells may CD40L administration. Alternatively, it is possible that
loss of CD40L function in the GC causes B cells tobe identified within the target organ, the lack of CD40L
would seriously compromise their ability to trigger mac- emigrate to the bone marrow and terminally differentiate
into plasma cells. This hypothesis would be consistentrophage functions optimally, like the production of pro-
inflammatory cytokines and inflammatory cytokines, the with a recent in vitro study that shows that the with-
drawal of CD40L results in memory B cells terminallyup-regulation of costimulatory molecules, and other me-
diators of inflammatory pathology. In sum, the role of differentiating to plasma cells (Arpin et al., 1995).
If the function of CD40L is so critical for GC mainte-CD40L at all of these levels of cell-mediated immunity
help to explain why one can so effectively interrupt the nance, which cells in the GC are expressing CD40L?
Our own collaborative studies in immune mice did notdevelopment of autoimmune disease and graft rejection
by the administration of anti-CD40L and why mice lack- detect CD40L in the GC of immune mice (Van den Eert-
wegh et al., 1993); however, other studies in humaning CD40±CD40L cannot mount effective cell-mediated
immune responses to parasites. tonsil have indicated its presence (Lederman et al., 1992;
Casamayor et al., 1995). Recently (Casamayor et al.,
1995), it has been shown that in human tonsil, a subset
New Issues Concerning the Role of CD40L of T cells contained preformed CD40L that could be
in the Genesis and Maintenance of Germinal mobilized rapidly upon activation. The T cells containing
Centers and Somatic Mutation preformed CD40L were found predominately in theouter
CD40L and Its Role in Germinal Center Formation zone of the GC and could be important cells for the
The early studies in CD40L2/2 and CD402/2 mice, and in maintenance of GC integrity. Regulation of CD40L ex-
mice treated with anti-CD40L, documented that primary pression by these T cells may well regulate the tempo
and secondary humoral immune responses were se- of the GC reaction.
verely impaired by the absence of CD40 signaling (Foy CD40L and Somatic Mutation
et al., 1993; Kawabe et al., 1994; Renshaw et al., 1994; With its prominent role in the regulation of B cell growth
Xu et al., 1994). In addition, germinal center (GC) forma- and differentiation, CD40L was a tempting candidate
tion in response to TD antigens was completely absent. for triggering the somatic hypermutation of IgV genes.
The interpretations of these studies suggested that sig- Since triggering of B cells through CD40 induces explo-
nals via CD40 were responsible for GC formation. Alter- sive B cell growth and differentiation (Banchereau et al.,
native insights into the formation of GCs have emerged 1994), it was of interest to determine whether CD40
from studies in CD402/2 mice. CD402/2 mice that were signaling and lymphokines also triggered B immuno-
administered CD40Ig (so as to engage CD40L) form a globulin hypermutation. Single naive B cells were cul-
limited number of small GCs. These data are interpreted tured in vitro with anti-CD40 and IL-4 and somatic muta-
to suggest that engagement of CD40L by CD40Ig trans- tions in the heavy chain V region were assessed. While
duces a costimulatory signal to T cells to elaborate an single B cells were shown to isotype switch to down-
activity that contributes to GC formation (van Essen et stream isotypes, an increase in the somatic mutation in
al., 1995). This is in agreement with earlier in vitro data IgH V genes could not be documented (Galibert et al.,
1995). An alternative system that appears to sustainthat also suggest that CD40L, when engaged by a
Immunity
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Durie, F.H., Foy, T.M., Masters, S.R., Laman, J.D., and Noelle, R.J.somatic mutation in vitro was recently reported (Kallberg
(1994b). Immunol. Today 15, 406±411.et al., 1996). B cells that were triggered by immunization
Foy, T.M., Aruffo, A., Ledbetter, J.A., and Noelle, R.J. (1993). J. Exp.in vivo, were isolated after at least 10 days, then cocul-
Med. 178, 1567±1575.tured with an alloreactive Th clone. Under these condi-
Galibert, L., van Dooren, J., Durand, I., Rousset, F., Jefferis, R.,tions, there was an increase in the number of Vk muta-
Banchereau, J., and Lebecque, S. (1995). Eur. J. Immunol. 25,tions. Interestingly, swapping the Th2 clone with CD40L
733±737.
was largely ineffective at inducing Vk mutations. Collec-
Gerritse, K., Noelle, R.J., Aruffo, A., Ledbetter, J., Laman, J.D., Boer-tively, these observations suggest that CD40L is neither sma, W.J.A., and Claassen, E. (1996). Proc. Nat. Acad. Sci. USA 93,
sufficient to initiate nor sustain somatic mutations. The 2499±2504.
success of others (Decker et al., 1995) in inducing so- Grewal, I.S., Xu, J., and Flavell, R.A. (1995). Nature 378, 617±20.
matic mutation in splenic fragments may suggest that
Griggs, N., Agersborg, S., Noelle, R., Ledbetter, J., Linsley, P., and
lymphoid architecture is a requirement, together with Tung, K. (1996). J. Exp. Med. 183, 801±810,
antigen-specific T cell help, for B cells to initiate somatic Han, S., Hathcock, K., Zheng, B., Kepler, T.B., Hodes, R., and Kelsoe,
mutation. G. (1995). J. Immunol. 155, 556±567.
Hathcock, K.S., Laszlo, G., Pucillo, C., Linsley, P., and Hodes, R.J.
(1994). J. Exp. Med. 180, 631±640.Conclusion
Hollenbaugh, D., Mischel-Petty, N., Edwards, C.P., Simon, J.C.,Den-
field, R.W., Kiener, P.A., and Aruffo, A. (1995). J. Exp. Med. 182,Over the past year, we have seen the function of CD40L
33±40.greatly expand from a molecule that was exclusively
Inaba, L., Witmer-Pack, M., Inaba, M., Hathcock, K.S., Sakuta, H.,involved in the regulation of TD humoral immune re-
Azuma, M., Yagita, H., Okumura, K., Linsley, P.S., Ikehara, S., Mara-sponses, to a molecule that signficantly contributes to
matsu, S., Hodes, R.J., and Steinman, R,M, (1994). J. Exp. Med.
the inflammatory process. Whether the function of 180, 1849±1860.
CD40L in the inflammatory process is essential, like its
Kallberg, E., Jainandunsing, S., Gray, D., and Leanderson, T. (1996).
function inTD humoral immunity, demandscritical atten- Science 271, 1285±1288.
tion. It isclear that at least some inflammatory responses
Kamanaka, M., Yu, P., Yasui, T., Yoshida, K., Kawabe, T., Horii, T.,
are intact in CD40L-defective mice and in HIM patients. Kishimoto, T., and Kikutani, H. (1996). Immunity 4, 275±281.
Therefore, the question emerges as to in which subset Karmann, K., Hughes, C.W., Schechner, J., Fanslow, W.C., and
of inflammatory responses does CD40L play a role? Pober, J.S. (1995). Proc. Natl. Acad. Sci. USA 92, 4342±4346.
Numerous studies have implied that CD40L plays an Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suemat-
indirect role in the priming of T cells; yet it is unclear at su, S., Yoshida, N., Kishimoto, T., and Kikutani, H. (1994). Immunity
this time whether T cellsprimed in the absence of CD40L 1, 167±178.
are anergic, ignorant, or physically deleted. The in vitro Kiener, P.A., Moran, D.P., Rankin, B.M., Wahl, A.F., Aruffo, A., and
Hollenbaugh, D. (1995). J. Immunol. 155, 4917±4925.studies on the potential role of this ligand in the regula-
tion of endothelial cell function are provocative; yet Larsen, C.P., Ritchie, S.C., Hendrix, R., Linsley, P.S., Hathcock, K.S.,
Hodes, R.J., Lowry, R.P., and Pearson, T.C. (1994). J. Immunol. 152,critical studies in vivo are needed to evaluate whether
5208±5219.CD40±CD40L interactions are involved in lymphocyte
Larsen, C.P., Alexander, D.Z., Hollenbaugh, D., Elwood, E.T., Ritchie,trafficking. With the expanding role of CD40 and its li-
S.C., Aruffo, A., Hendrix, R., and Pearson, T.C. (1996). Transplanta-gand, clear answers to its function in regulating the
tion 61, 4±9.immune response may only be resolved by interfering
Lederman, S., Yellin, M.J., Inghirami, G., Lee, J.J., Knowles, D.M.,with CD40 signaling in a tissue- or cell-specific fashion.
and Chess, L. (1992). J. Immunol. 149, 3817±3826.
Liu, Y.J., Johnson, G.D., Gordon, J., and MacLennan, I.C. (1992).
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